Monument Therapeutics partners on novel treatment for schizophrenia
Monument Therapeutics and the Foundation for the National Institutes of Health (FNIH) will evaluate MT1988, in development for cognitive impairment associated with schizophrenia, in a proof-of-principle clinical trial. Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis, referred to as… Read More